FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313238738> ?p ?o ?g. }

• W4313238738 endingPage "6" @default.
• W4313238738 startingPage "6" @default.
• W4313238738 abstract "There is growing evidence of the association of Microscopic Colitis (MC) with the use of specific medications such as proton pump inhibitors (PPIs), Selective serotonin reuptake inhibitors (SSRIs), Non-Steroidal anti-inflammatory drugs (NSAIDs), Statins and H2-receptor antagonists (H2RA). In our study, we calculated the pooled odds of MC in patients using these drugs. We performed a detailed search of major databases, including PubMed/Medline, Scopus, web of science, and Embase, to include the studies in which odds of MC were reported after using above mentioned drugs. A random-effects model was used to pool the estimates. Thirteen studies were included in our analysis consisting of 304,482 patients (34,194 cases and 270,018 controls). In eight studies, the control group consisted of a random population selected based on age, gender and same birth year, whereas 3 studies recruited patients who presented with diarrhea and underwent colonoscopy and biopsy to rule out MC. Two studies reported odds of MC for both diarrhea and random control groups. Patients taking PPIs were more likely to develop MC, AOR 2.65 (95% CI 1.81-3.50, I2 98.13%). Similarly, higher odds of association were found in patients taking SSRIs (OR 2.12, 95% CI 1.27-2.96, I2 96.46%), NSAIDs (OR 2.02, 95% CI 1.33-2.70, I2 92.70%) and Statins (OR 1.74, 95% CI 1.19-2.30, I2 96.36%). No difference in odds of developing MC was seen in patients using H2RA compared to the control group (OR 2.70, 95% CI 0.32-5.08, I2 98.67%). We performed a subgroup analysis based on the control group and found higher odds of MC in patients on PPIs compared to the random control group (OR 4.55, 95% CI 2.90-6.19, I2 98.13%). Similarly, higher odds of MC were noted for SSRI (OR 3.23, 95% CI 1.54-4.92, I2 98.31%), NSAIDs (OR 3.27, 95% CI 2.06-4.48, I2 95.38%), and Statins (OR 2.23, 95% CI 1.41-3.06, I2 98.11%) compared to the random control group. Contrary lower odds of MC were seen in the PPI and H2RA group compared to the diarrhea control group (OR 0.68, 95% CI 0.48-0.88, I2 7.26%), (OR 0.46, 95% CI 0.14-0.78, I2 0%) respectively. We found no difference in odds of MC in patients on SSRIs (OR 0.96, 95% CI 0.49-1.42, I2 37.89%), NSAIDs (OR 1.13, 95% CI 0.49-1.76, I2 59.37%) Statins (OR 0.91, 95% 0.66-1.17, I2 0%) and H2RA (OR 3.48, 95% CI -0.41-7.36, I2 98.89%) compared to the diarrhea control group. We also analyzed the association use of PPIs and NSAIDs with the development of collagenous colitis (CC) and lymphocytic colitis. Only the use of NSAIDs was associated with increased odds of developing collagenous colitis (OR 1.61, 95% CI 1.50-1.72, I2 0%). No increased odds of CC and LC were seen in PPI users. PPIs, NSAIDs, SSRIs, and Statins are associated with an increased risk of MC compared to the random control group. On the contrary, the use of PPIs, NSAIDs, SSRIs, and Statins is not associated with an increased risk of MC when compared to the diarrhea control group." @default.
• W4313238738 created "2023-01-06" @default.
• W4313238738 creator A5005496868 @default.
• W4313238738 creator A5011349477 @default.
• W4313238738 creator A5022410967 @default.
• W4313238738 creator A5024732707 @default.
• W4313238738 creator A5031254128 @default.
• W4313238738 creator A5071437558 @default.
• W4313238738 creator A5084270299 @default.
• W4313238738 creator A5089202095 @default.
• W4313238738 date "2022-12-29" @default.
• W4313238738 modified "2023-09-30" @default.
• W4313238738 title "Are Drugs Associated with Microscopic Colitis? A Systematic Review and Meta-Analysis" @default.
• W4313238738 cites W105836756 @default.
• W4313238738 cites W1874766091 @default.
• W4313238738 cites W190120881 @default.
• W4313238738 cites W1977262801 @default.
• W4313238738 cites W1977282936 @default.
• W4313238738 cites W1996088849 @default.
• W4313238738 cites W2014291574 @default.
• W4313238738 cites W2017044005 @default.
• W4313238738 cites W2036694137 @default.
• W4313238738 cites W2053050463 @default.
• W4313238738 cites W2063066707 @default.
• W4313238738 cites W2067093184 @default.
• W4313238738 cites W2080694161 @default.
• W4313238738 cites W2089867690 @default.
• W4313238738 cites W2092823242 @default.
• W4313238738 cites W2093380437 @default.
• W4313238738 cites W2093573853 @default.
• W4313238738 cites W2125123579 @default.
• W4313238738 cites W2152530781 @default.
• W4313238738 cites W2194591433 @default.
• W4313238738 cites W2294580066 @default.
• W4313238738 cites W2313273860 @default.
• W4313238738 cites W2530607369 @default.
• W4313238738 cites W2559448577 @default.
• W4313238738 cites W2884943040 @default.
• W4313238738 cites W2922476638 @default.
• W4313238738 cites W3023200119 @default.
• W4313238738 cites W3080354643 @default.
• W4313238738 cites W3123893780 @default.
• W4313238738 cites W3156935299 @default.
• W4313238738 cites W3175281922 @default.
• W4313238738 cites W3182491679 @default.
• W4313238738 cites W3200148634 @default.
• W4313238738 cites W4213008232 @default.
• W4313238738 cites W876370766 @default.
• W4313238738 doi "https://doi.org/10.3390/diseases11010006" @default.
• W4313238738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36648871" @default.
• W4313238738 hasPublicationYear "2022" @default.
• W4313238738 type Work @default.
• W4313238738 citedByCount "0" @default.
• W4313238738 crossrefType "journal-article" @default.
• W4313238738 hasAuthorship W4313238738A5005496868 @default.
• W4313238738 hasAuthorship W4313238738A5011349477 @default.
• W4313238738 hasAuthorship W4313238738A5022410967 @default.
• W4313238738 hasAuthorship W4313238738A5024732707 @default.
• W4313238738 hasAuthorship W4313238738A5031254128 @default.
• W4313238738 hasAuthorship W4313238738A5071437558 @default.
• W4313238738 hasAuthorship W4313238738A5084270299 @default.
• W4313238738 hasAuthorship W4313238738A5089202095 @default.
• W4313238738 hasBestOaLocation W43132387381 @default.
• W4313238738 hasConcept C121608353 @default.
• W4313238738 hasConcept C126322002 @default.
• W4313238738 hasConcept C143095724 @default.
• W4313238738 hasConcept C151956035 @default.
• W4313238738 hasConcept C156957248 @default.
• W4313238738 hasConcept C2778260677 @default.
• W4313238738 hasConcept C2778435480 @default.
• W4313238738 hasConcept C2778561856 @default.
• W4313238738 hasConcept C2779134260 @default.
• W4313238738 hasConcept C2908647359 @default.
• W4313238738 hasConcept C526805850 @default.
• W4313238738 hasConcept C71924100 @default.
• W4313238738 hasConcept C90924648 @default.
• W4313238738 hasConcept C95190672 @default.
• W4313238738 hasConcept C99454951 @default.
• W4313238738 hasConceptScore W4313238738C121608353 @default.
• W4313238738 hasConceptScore W4313238738C126322002 @default.
• W4313238738 hasConceptScore W4313238738C143095724 @default.
• W4313238738 hasConceptScore W4313238738C151956035 @default.
• W4313238738 hasConceptScore W4313238738C156957248 @default.
• W4313238738 hasConceptScore W4313238738C2778260677 @default.
• W4313238738 hasConceptScore W4313238738C2778435480 @default.
• W4313238738 hasConceptScore W4313238738C2778561856 @default.
• W4313238738 hasConceptScore W4313238738C2779134260 @default.
• W4313238738 hasConceptScore W4313238738C2908647359 @default.
• W4313238738 hasConceptScore W4313238738C526805850 @default.
• W4313238738 hasConceptScore W4313238738C71924100 @default.
• W4313238738 hasConceptScore W4313238738C90924648 @default.
• W4313238738 hasConceptScore W4313238738C95190672 @default.
• W4313238738 hasConceptScore W4313238738C99454951 @default.
• W4313238738 hasIssue "1" @default.
• W4313238738 hasLocation W43132387381 @default.
• W4313238738 hasLocation W43132387382 @default.
• W4313238738 hasLocation W43132387383 @default.
• W4313238738 hasOpenAccess W4313238738 @default.

• next